Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 127,710

Document Document Title
WO/2017/193563A1
A composition, and an application and pharmaceutical preparation thereof. The invention provides a plurality of novel compositions and preparations comprising a berberine in combination with EPA and DHA, and an application thereof for tr...  
WO/2017/190708A1
Provided in the present invention are a compound as represented by formula (I), a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, and a hydrate thereof or a pharmaceutically acceptable salt and ester thereof, a...  
WO/2017/192858A1
The present disclosure is directed to oxazoline mono- and hetero-pseudodimer compounds, such as compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: These compounds are useful for treating pain. The present ...  
WO/2017/191000A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2017/190263A1
Provided are derivatives of a snake venom C fragment straight-chain polypeptide and a cyclic peptide related thereto, and a preparation method therefor. The derivatives comprise a parent peptide sequence as shown in formula I: R1-P1-Asp-...  
WO/2017/192942A1
Described herein are novel methods and compositions useful in modulating the permeability of a P-glycoprotein expressing barrier of a tissue or an organ, such as the blood- brain barrier, of a subject and improving transport of an agent ...  
WO/2017/190568A1
Disclosed are an amine solvate of a sodium-glucose linked transporter (SGLT) inhibitor, and a preparation method and application thereof. The SGLT inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl) methyl)-4-ethylb...  
WO/2017/190526A1
The present invention belongs to the technical field of drugs, and relates in particular to an application of a tetramethylpyrazine derivative tetramethylpyrazine nitrone in the preparation of a drug and the prevention and treatment of b...  
WO/2017/190707A1
Disclosed are a compound as shown in formula (I), cis-and trans-isomers, an enantiomer, diastereoisomer, racemate, solvate and hydrate thereof, or a pharmaceutically acceptable salt and ester, a preparation method thereof, a pharmaceutic...  
WO/2017/190681A1
An antidepressant and screening method thereof. An active pharmaceutical ingredient of the antidepressant targets a dendritic-cell-associated C-type lectin-1. The antidepressant exerts an antidepressant effect by binding, activating, and...  
WO/2017/190714A1
The present invention relates to chemistry, pharmaceutics, and in particular to the production of formulations from derivatives of phenol compounds or polyphenol compounds and from derivatives of phenol compounds or polyphenol compounds ...  
WO/2017/191304A1
The present invention relates to new compounds of general formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially α2δ-1 subunit of voltage-gated calcium channels ...  
WO/2017/192929A1
The invention provides substituted pyrrolo[1,2-α]triazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gauche...  
WO/2017/191034A1
The present invention relates to a compound having the following formula (I) : (I), in which: - X is O or S; - A is an aromatic (hetero)cycle comprising from 5 to 10 atoms chosen from carbon and nitrogen atoms, which is optionally substi...  
WO/2017/190682A1
The present invention discloses a novel crystalline form E of a tafamidis methylglucamine salt, and a preparation method and application thereof. When compared to other known crystalline forms, the new crystalline form provided in the in...  
WO/2017/191351A1
The present invention relates to delayed-release methylphenidate tablets characterized in that they are provided with a release-controlling layer comprising a combination of an enteric polymer and a hydrophobic agent. These tablets have ...  
WO/2017/191838A1
The invention provides a safe and stable plasmalogen, a formulation thereof, and a method for assessing presymptomatic dementia. More specifically, the invention comprises: a supplement or a foodstuff as a processed product for the mitig...  
WO/2017/192930A1
The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and comp...  
WO/2017/192538A1
The invention provides TrkB agonist antibodies or antigen-binding fragments that specifically enhance TrkB signaling activities. The invention also provides therapeutic methods of using such antibodies for promoting survival and regenera...  
WO/2017/192841A1
The invention provides methods of treatment and combination therapies using heterobicyclic and related compounds that activate Gcase, such as in the treatment of endometriosis and Parkinson's disease. An exemplary heterobicyclic compound...  
WO/2017/192906A1
The present application provides methods for treating human subjects suffering from Rett Syndrome by administering PKC activators, for example, bryostatin 1, other bryostatins and bryologs. The present disclosure provides, according to c...  
WO/2017/192931A1
The invention provides substituted imidazo[1,2-α]pyridine compounds, substituted imidazo[1,2-α]pyrazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compos...  
WO/2017/191638A1
The instant invention provides methods and compositions which are applicable for modulating, preventing or treating non-clinical and clinical conditions that are associated with composition of mammalian microbiome. Methods and compositio...  
WO/2017/187336A4
The present invention relates to pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/185900A1
Provided are a series of crocins compounds and related pharmacological application thereof in prevention and treatment of Alzheimer's disease. The series of crocins compounds are obtained by taking the Chinese herb, namely Gardenia jasmi...  
WO/2017/185959A1
Fused imidazole derivatives having IDO/TDO inhibiting activity and having the structure of formula (I), and a preparation method and use therefor. The series of fused imidazole derivatives has a high degree of inhibiting activity against...  
WO/2017/186686A1
The present invention relates to the use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in patients suffering from a CNS disease, in particular patients with Parkin- son's disease, wherein balance, gait or movem...  
WO/2017/185249A1
The present application provides a peptide comprising an amino acid sequence of YEKLLDTEI (SEQ ID NO: 1) or a functional variant thereof. The peptide is a bioactivee peptide for the treatment of central nervous system injuries. The prese...  
WO/2017/186924A1
Stable crystal forms comprising lithium ions and the conjugate base of an organic acid which is in the form of anhydrous coordination polymer that exhibit improved in vivo performance with respect to lithium carbonate.  
WO/2017/187176A1
The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional...  
WO/2017/187352A1
The invention relates to a new class of compounds of formula (I) targeting COX-1. The invention also relates to the use of some of such compounds as a tool to investigate the structure and function of the enzyme, in the treatment targeti...  
WO/2017/188403A1
The purpose of the present invention is to provide a new mesenchymal stem cell having excellent therapeutic effects for various diseases, a new pharmaceutical composition containing the mesenchymal stem cell, and methods for preparing th...  
WO/2017/187340A4
The invention is directed to a pharmaceutical combination composition comprising stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lum...  
WO/2017/186919A1
The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-c arboximioyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), fo...  
WO/2017/188457A1
The present invention relates to a synapse formation accelerant and a brain plasticity accelerant that contain CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow fluid, as well as to treatment of dementia, chr...  
WO/2017/186934A1
The invention relates to dipeptidyl peptidase-4 inhibitors, including saxagliptin and sitagliptin, for use in the topical eye treatment and/or prevention of retinal neurodegenerative diseases, in particulardiabetic retinopathyand its ass...  
WO/2017/185899A1
A composition, and a crocins active site extracted from Gardenia jasminoides Ellis, mainly comprising the following ingredients: crocetin di-β-D-gentiobioside, crocetin-β-D-glucopyranosyl-β-D-gentiobioside, crocetin di-β-D-glucopyran...  
WO/2017/188365A1
A medicine for preventing and/or treating multiple sclerosis, particularly pain such as neuropathic pain associated with multiple sclerosis and the like, said medicine containing, as an active ingredient, a compound having an antagonisti...  
WO/2017/189951A1
A method for evaluating a subject's risk of developing glaucoma, or having glaucoma, or having glaucoma that will progress in severity comprising determining from a biological sample from a subject whether the patient has a mitochondrial...  
WO/2017/188260A1
In some embodiments, a composition of matter includes aripiprazole, a metal selected from the group consisting of magnesium, zinc, sodium, lithium, iron, or alloys thereof, or combinations thereof and a copper salt selected from the grou...  
WO/2017/187338A4
The present invention relates to pharmaceutically acceptable complex formulation comprising complexes of Lumacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/189375A1
A chewing gum composition comprising cannabinoids or derivatives thereof and nicotine in the form of nicotine polacrilex is provided. The chewing gum composition is formulated to provide rapid and controlled release of cannabinoids and n...  
WO/2017/187338A1
The present invention relates to pharmaceutically acceptable complex formulation comprising complexes of Lumacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/187340A1
The invention is directed to a pharmaceutical combination composition comprising stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lum...  
WO/2017/187336A1
The present invention relates to pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/185250A1
Provided in the present application is a peptide containing the amino acid sequence YEKLTTLDTGGV (SEQ ID NO:1) or a functional variant thereof, the peptide being an active peptide for treating central nervous system injury. Also provided...  
WO/2017/181585A1
The present invention relates to the technical field of medicine, and specifically relates to a PUMA inhibitor, a method for preparation thereof, and a use thereof. The PUMA inhibitor is the compound as shown in (I) or a pharmaceutically...  
WO/2017/181790A1
A neutron capture therapy system for eliminating an amyloid β-protein plaque. The system comprises: a neutron capture therapy device and a compound comprising 10B, wherein the compound can specifically bind to an amyloid β-protein plaq...  
WO/2017/185061A1
The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.  
WO/2017/181811A1
Disclosed are an opctahydroanthracene compound as represented by formula (I) or (II), a preparation method for same, and uses of same, which provides great therapeutic effects for tumors and neurodegenerative diseases and is prepared mai...  

Matches 301 - 350 out of 127,710